The Company stated that the CoviFind for at-home self- Covid testing is highly effective in providing results for individuals infected with mid to high Covid viral load in about 15 minutes, with the help of its app. CoviFind is priced at ₹250 and will be available in two weeks at retail pharmacies, e-pharmacies and e-commerce platforms including Amazon and Flipkart. The company will also sell and distribute the product through direct orders of the test kit on its website.
“Nasal swabs only have to be inserted 2 to 4 centimetres (cms) into a patient’s nose, as compared to the alternative nasopharyngeal swab that needs to be inserted 8 to 10 cms into the nasopharynx for adults,” the company said.
Sanjeev Bhatt, Sr. Vice President, Corporate Strategy, Meril, said, “We believe CoviFind will be a valuable tool to address the ongoing public health crisis while easing the burden on health systems and labs. This home test is the latest addition to our comprehensive Covid-19 testing portfolio, which has been supporting both public and private testing in the fight against the pandemic. We aim to continue contributing to the rise of self-reliance or Atmanirbharta in diagnostics.”